Pneumo 23
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT02052154 | Mar 2014 → Jul 2016 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT02274415 | Sep 2013 → Sep 2017 | pneumococcal infection, sickle cell disease | Assistance Publique - Hôpitaux de Paris | Completed | Met primary |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT00999739 | Dec 2007 → Apr 2008 | HIV infectious disease | Hospital Universitari Son Dureta | Unknown | Missed primary |
| Phase 3 | NCT00594347 | Nov 2007 → Mar 2008 | pneumococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00169507 | Mar → Apr 2005 | idiopathic severe pneumococcemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT02787863 | Sep 2012 → Dec 2016 | asthma, chronic obstructive pulmonary disease, pneumococcal infection | Mikhael Petrovich Kostinov | Completed | Met primary |
| Phase 4 | NCT00368186 | May 2001 → Nov 2002 | pneumococcal infection | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Comparator or background therapy10 trials | ||||||
| Phase 1 | NCT00756067 Comparator | Sep 2008 → May 2009 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00707798 Comparator | Jun 2008 → Jan 2009 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00327665 Comparator | May 2006 → Jan 2007 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02255227 Background | Apr 2015 → Aug 2019 | inflammatory bowel disease, pneumococcal infection | University Hospital of Saint-Etienne | Terminated | No outcome recorded |
| Phase 2 | NCT02279589 Comparator | Dec 2014 → Jun 2016 | pneumococcal infection | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2/3 | NCT00611663 Background | May 2008 → Dec 2014 | systemic lupus erythematosus | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 2/3 | NCT00339157 Comparator | May 2006 → Jun 2008 | systemic-onset juvenile idiopathic arthritis | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 3 | NCT01942174 Background | Sep 2013 → Aug 2018 | rheumatoid arthritis | University Hospital, Montpellier | Completed | Met primary |
| — | NCT02547493 Comparator | Mar 2016 → Jan 2021 | rheumatoid arthritis | University Hospital, Montpellier | Completed | No outcome recorded |
| — | NCT02538211 Comparator | Sep 2015 → Jan 2017 | Rotavirus infection, post-bacterial disorder, streptococcal pneumonia, tetanus | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumo23 | “Primed group: 50 subjects who previously received 4 doses of GSK Biologicals' 11Pn-PD vaccine will receive 1 dose of Pneumo 23 Unprimed group (Control): 50 subjects who...” NCT00169507 ↗19“PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the...” NCT02547493 ↗ “All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.” NCT02538211 ↗ “There are two types of anti-pneumococcal vaccines: firstly a polysaccharide, Pneumo23® (PSV-23®) vaccine and secondly a conjugate, Prevenar13® vaccine.” NCT02255227 ↗ “23-valent pneumococcal capsular polysaccharide vaccine (Pneumo23(®) [PPV23], Sanofi Pasteur)” PMID 25424793 ↗ 2014 “The Pneumo23® has been for a long time the only vaccine recommended in adults” NCT02279589 ↗ “Pneumo23® or Pneumovax® polysaccharide vaccine (PPSV)” NCT02052154 ↗ |
| Known as | 23PPV | “single dose of the control 23-valent pneumococcal polysaccharide vaccine (23PPV; Pneumovax23™, Sanofi Pasteur MSD) followed by placebo” PMID 24607003 ↗ Mar 2014 |
| Known as | Pneumo23 (23valent polysaccharide pneumococcal vaccine) | “Pneumo23 (23valent polysaccharide pneumococcal vaccine)” NCT00999739 ↗ |
| Known as | Pneumo23/Pneumovax | “Pneumo23/Pneumovax” NCT02547493 ↗ |
| Known as | Pneumovax | “PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the...” NCT02547493 ↗2“Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company” NCT01942174 ↗ “Pneumo23® or Pneumovax® polysaccharide vaccine (PPSV)” NCT02052154 ↗ |
| Known as | Pneumovax23 | “single dose of the control 23-valent pneumococcal polysaccharide vaccine (23PPV; Pneumovax23™, Sanofi Pasteur MSD) followed by placebo” PMID 24607003 ↗ Mar 2014 |
| Known as | PPV23 | “23-valent pneumococcal capsular polysaccharide vaccine (Pneumo23(®) [PPV23], Sanofi Pasteur)” PMID 25424793 ↗ 2014 |
| Known as | PSV-23 | “There are two types of anti-pneumococcal vaccines: firstly a polysaccharide, Pneumo23® (PSV-23®) vaccine and secondly a conjugate, Prevenar13® vaccine.” NCT02255227 ↗ |
| Modality | Vaccine | “a Licensed Non-GlaxoSmithKline Biologicals' Vaccine” NCT00327665 ↗ |
| Route | Intramuscular | “Single-dose intramuscular injection.” NCT00327665 ↗ |